Neurocrine Biosciences (Brazil) Today
| N1BI34 Stock | 36.16 0.49 1.37% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Neurocrine Biosciences is trading at 36.16 as of the 24th of November 2024, a 1.37% up since the beginning of the trading day. The stock's open price was 35.67. Neurocrine Biosciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Neurocrine Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of November 2023 and ending today, the 24th of November 2024. Click here to learn more.
Moving against Neurocrine Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Neurocrine Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Neurocrine Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Neurocrine Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Kevin Gorman |
| Business Concentration | Drug Manufacturers-Specialty & Generic (View all Sectors) |
Neurocrine Biosciences (N1BI34) is traded on Sao Paulo Exchange in Brazil and employs 1,200 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 51.64 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Neurocrine Biosciences has 1.93 B outstanding shares.
Neurocrine Biosciences generates positive cash flow from operations, but has no cash available
Check Neurocrine Biosciences Probability Of Bankruptcy
Neurocrine Biosciences Risk Profiles
Although Neurocrine Biosciences' alpha and beta are two of the key measurements used to evaluate Neurocrine Biosciences' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.35 | |||
| Standard Deviation | 2.83 | |||
| Variance | 8.02 | |||
| Risk Adjusted Performance | (0.04) |
Neurocrine Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Neurocrine Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Neurocrine Biosciences Corporate Management
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Cooke | Chief Officer | Profile | |
| Matthew Abernethy | Chief Officer | Profile | |
| Jane Sorensen | Head Relations | Profile | |
| Eiry MD | Chief Officer | Profile | |
| Eric Benevich | Chief Officer | Profile | |
| Darin Lippoldt | Chief Sec | Profile | |
| Jude Onyia | Chief Officer | Profile |
Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.